Innate Pharma announces conference call and webcast for full year 2024 financial results
Innate Pharma To Participate In The 2025 Leerink Partners Global Healthcare Conference
Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome
Innate Pharma announces first patient dosed in Phase 1 study of its Nectin-4 targeting antibody drug conjugate IPH4502 in selected advanced solid tumors
Innate Pharma announces Nectin-4 antibody drug conjugate investor and analyst event in New York
Number of shares and voting rights of Innate Pharma as of December 31, 2024
Innate Pharma announces transformative strategy to accelerate growth
Innate Pharma to participate in the 43rd Annual J.P. Morgan Healthcare Conference
Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024 from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announce up to $7.9m investment from IFLI to support IPH6501 development in Follicular Lymphoma
